TARS Projected Dividend Yield
Tarsus Pharmaceuticals Inc ( NASDAQ : TARS )Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. Co. is focused on the development and commercialization of therapeutics, starting with eye care. Co.'s lead product candidate, XDEMVY is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. 21 YEAR PERFORMANCE RESULTS |
TARS Dividend History Detail TARS Dividend News TARS Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |